Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is obtainable as monotherapy in each subcutaneous as well as oral dosage form (1st permitted oral GLP-1 receptor agonist). It has been authorised as a 2nd line cure choice for better glycaemic Handle in variety 2 diabetes and currently under scrutiny for https://jq-1-uses-in-cancer-rese91345.humor-blog.com/31023716/not-known-factual-statements-about-jq-1-research-studies